NxPharmaGen Information

NX PharmaGen Inc. was founded to invest in technologies that have the potential to enrich the lives of patients. Application of our next-generation molecular diagnostics and imaging products will benefit patient outcomes, physician decision making, and payer economics, while also accelerating the testing and approval of new interventions. NX Development Corp. was spun out of NX PharmaGen and fostered the FDA approval and US launch of an important new imaging tool for brain tumor patients. Gleolan is a fluorescence-guided resection imaging agent for malignant glioma cases. NXDC was acquired in 2018. Please visit www.nxdevcorp.com to learn more. NX Prenatal Inc. was spun out of NX PharmaGen to develop exosome-based diagnostics in the large maternal-fetal-infant health field. Through a series of human clinical studies and peer-reviewed publications, NX Prenatal is the only company in the world to have demonstrated an ability to detect biomarker panels derived from circulating maternal-fetal exosomes as early as week 10-12 of gestation that are predictive of adverse pregnancy outcomes such as Preterm Birth and Preeclampsia. Please visit www.nxprenatal.com to learn more The Nexosome Oncology division of NX PharmaGen is focused on the applications of exosome-based diagnostics in the cancer field. Findings to date confirm that employing an exosome-focused liquid biopsy approach to cancer can reveal fingerprints of the ever-changing molecular machinery of tumor cells, including information that can help predict and evaluate responsiveness and resistance to therapeutics. Please visit www.nexosome-oncology.com to learn more.